This week in oncology, regulatory updates and practice-changing trial data took center stage. From FDA timeline extensions to ...
According to a recent systematic review published in JCO Oncology Practice, implementation of same-day multidisciplinary ...
Despite major advances in targeted therapy, chronic lymphocytic leukemia (CLL) remains largely incurable. Resistance to ...
The Centers for Medicare & Medicaid Services has issued a permanent billing and reimbursement J-code, J9183, for the ...
As treatment options expand in chronic lymphocytic leukemia (CLL), the benefits and limitations of fixed-duration regimens in ...
The investigators note that the lower rate of feeding-tube placement with IMPT at the end of treatment, combined with a ...
Concurrent statin therapy was associated with significantly improved survival outcomes and reduced neurotoxicity in patients ...
The FDA granted fast track designation to PAS-004, a macrocyclic MEK inhibitor, for NF1-associated plexiform neurofibromas ...
In this segment focused on advanced renal cell carcinoma, Dr. Geynisman shifts the discussion to patients with intermediate ...
The FDA has granted Fast Track Designation to CTIM-76, a claudin-6 (CLDN6) x CD3 T cell engaging bispecific antibody, for the ...
Young US cancer survivors face outsized food, housing and transport insecurity; Medicaid expansion and targeted SDOH ...
Dr Thomas Flaig from the University of Colorado Anschutz discusses a paradigm shift in treating urothelial carcinoma patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results